- Voyageur Pharmaceuticals (VM) has initiated its marketing campaign to introduce SmoothX barium sulfate CT contrast media to the CT Imaging market in Canada
- SmoothX is a generic oral barium sulfate contrast media product designed to assist in diagnosing disease using computed tomography (CT) scans
- The company also announced a non-brokered private placement for gross proceeds of up to C$650,000
- Brent Willis, Voyageur CEO, sat down with Daniella Atkinson to discuss the news
- Voyageur is focused on the development of barium, iodine, and carbon APIs, as well as imaging contrast agents for the medical radiology marketplace
- Voyageur Pharmaceuticals (VM) opened trading at $0.09 per share
Voyageur Pharmaceuticals (VM) has introduced SmoothX barium sulfate CT contrast media to the CT Imaging market in Canada.
SmoothX is a generic oral barium sulfate contrast media product designed to assist in diagnosing disease using computed tomography (CT) scans. It works by coating the gastrointestinal tract with barium sulfate so that diseased or damaged areas become visible by the CT scan.
Voyageur has completed the design of its Frances Creek barium processing facility and initiated a notice of work for the intent to extract 2,000 tonnes from the Frances Creek high-grade barium sulfate project, in 2023, with full-scale quarry mining planned in 2024. The property contains an indicated resource of 214,800 tonnes grading 35.2 per cent BaSO4 and an inferred resource of 134,200 tonnes of 33.9 per cent BaSO4. By selling the barium sulfate as contrast media, Voyageur expects to achieve high gross margins, verified in a preliminary economic assessment (PEA) by SGS Canada Inc.
The company also announced a non-brokered private placement for gross proceeds of up to C$650,000.
Brent Willis, Voyageur CEO, sat down with Daniella Atkinson to discuss the news.
Voyageur’s objective is to create a fully integrated, secure, environmentally responsible supply chain of barium, iodine, and fullerene contrast media for the North American and global markets.
Voyageur is focused on the development of barium, iodine, and carbon APIs, as well as imaging contrast agents for the medical radiology marketplace
Voyageur Pharmaceuticals (VM) opened trading at $0.07 per share.
